The Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis is 5 Modulated by the Genetic Background

21 Fluoroquinolones (FQ) form the backbone in experimental treatment regimens against 22 drug-susceptible tuberculosis. However, little is known on whether the genetic variation present 23

[1]  T. Clark,et al.  Genome-wide analysis of Mycobacterium tuberculosis polymorphisms reveals lineage-specific associations with drug resistance , 2019, BMC Genomics.

[2]  John L. Johnson,et al.  A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis , 2018, Nature Medicine.

[3]  T. Clark,et al.  Global expansion of Mycobacterium tuberculosis lineage 4 shaped by colonial migration and local adaptation , 2018, Science Advances.

[4]  John L. Johnson,et al.  Bacterial Factors That Predict Relapse after Tuberculosis Therapy , 2018, The New England journal of medicine.

[5]  L. Rigouts,et al.  Reference set of Mycobacterium tuberculosis clinical strains: A tool for research and product development , 2018, bioRxiv.

[6]  Alimuddin Zumla,et al.  Accelerating the development of therapeutic strategies for drug-resistant tuberculosis , 2018, Nature Reviews Drug Discovery.

[7]  S. Gagneux.  Ecology and evolution of Mycobacterium tuberculosis , 2018, Nature Reviews Microbiology.

[8]  Christian Beisel,et al.  Treemmer: a tool to reduce large phylogenetic datasets with minimal loss of diversity , 2018, BMC Bioinformatics.

[9]  E. Eugenin,et al.  Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum , 2017, Antimicrobial Agents and Chemotherapy.

[10]  Antoine Frénoy,et al.  Death and population dynamics affect mutation rate estimates and evolvability under stress in bacteria , 2017, bioRxiv.

[11]  M. Murray,et al.  Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Lamers,et al.  High-fidelity DNA replication in Mycobacterium tuberculosis relies on a trinuclear zinc center , 2017, Nature Communications.

[13]  D. Andersson,et al.  Evolutionary Trajectories to Antibiotic Resistance. , 2017, Annual review of microbiology.

[14]  Brendan Prideaux,et al.  Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach , 2017, PLoS Comput. Biol..

[15]  A. Narechania,et al.  Transmission of Extensively Drug‐Resistant Tuberculosis in South Africa , 2017, The New England journal of medicine.

[16]  D. Hughes,et al.  Mutation Supply and Relative Fitness Shape the Genotypes of Ciprofloxacin-Resistant Escherichia coli , 2017, Molecular biology and evolution.

[17]  Andrew Kitchen,et al.  Armed conflict and population displacement as drivers of the evolution and dispersal of Mycobacterium tuberculosis , 2016, Proceedings of the National Academy of Sciences.

[18]  S. Gandra,et al.  Poverty and prevalence of antimicrobial resistance in invasive isolates. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[19]  Liliana K. Rutaihwa,et al.  Mycobacterium tuberculosis Lineage 4 comprises globally distributed and geographically restricted sublineages , 2016, Nature Genetics.

[20]  R. MacLean,et al.  Epistasis between antibiotic resistance mutations and genetic background shape the fitness effect of resistance across species of Pseudomonas , 2016, Proceedings of the Royal Society B: Biological Sciences.

[21]  Xilin Zhao,et al.  Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones , 2016, Nucleic acids research.

[22]  P. de Rijk,et al.  Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis , 2016, The Journal of antimicrobial chemotherapy.

[23]  J. Berger,et al.  Crystal structure and stability of gyrase–fluoroquinolone cleaved complexes from Mycobacterium tuberculosis , 2016, Proceedings of the National Academy of Sciences.

[24]  N. Osheroff,et al.  Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase , 2016, Proceedings of the National Academy of Sciences.

[25]  L. Rigouts,et al.  Specific gyrA gene mutations predict poor treatment outcome in MDR-TB , 2015, The Journal of antimicrobial chemotherapy.

[26]  M. Chase,et al.  DNA replication fidelity in Mycobacterium tuberculosis is mediated by an ancestral prokaryotic proofreader , 2015, Nature Genetics.

[27]  Q. Zeng,et al.  Evolution of extensively drug-resistant tuberculosis over four decades revealed by whole genome sequencing of Mycobacterium tuberculosis from KwaZulu-Natal, South Africa , 2015 .

[28]  A. Crook,et al.  Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.

[29]  P. Butcher,et al.  High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. , 2014, The New England journal of medicine.

[30]  V. Furió,et al.  Testing the Role of Genetic Background in Parallel Evolution Using the Comparative Experimental Evolution of Antibiotic Resistance , 2014, Molecular biology and evolution.

[31]  Jukka Corander,et al.  Evolution and transmission of drug resistant tuberculosis in a Russian population , 2014, Nature Genetics.

[32]  Jeffrey E. Barrick,et al.  Genome dynamics during experimental evolution , 2013, Nature Reviews Genetics.

[33]  Daniel C. Angst,et al.  The cost of antibiotic resistance depends on evolutionary history in Escherichia coli , 2013, BMC Evolutionary Biology.

[34]  Marc Lipsitch,et al.  Mycobacterium tuberculosis mutation rate estimates from different lineages predict substantial differences in the emergence of drug resistant tuberculosis , 2013, Nature Genetics.

[35]  Marisa Klopper,et al.  Epistasis between antibiotic resistance mutations drives the evolution of extensively drug-resistant tuberculosis , 2013, Evolution, medicine, and public health.

[36]  Benjamin Kerr,et al.  Evolutionary rescue from extinction is contingent on a lower rate of environmental change , 2013, Nature.

[37]  P. V. van Helden,et al.  Putative Compensatory Mutations in the rpoC Gene of Rifampin-Resistant Mycobacterium tuberculosis Are Associated with Ongoing Transmission , 2012, Antimicrobial Agents and Chemotherapy.

[38]  K. Mitruka,et al.  Treatment Duration for Patients with Drug-Resistant Tuberculosis, United States , 2012, Emerging infectious diseases.

[39]  Hansjakob Furrer,et al.  Effect of Mutation and Genetic Background on Drug Resistance in Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[40]  T. Sterling,et al.  A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. , 2012, The Journal of antimicrobial chemotherapy.

[41]  S. Müller,et al.  Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background , 2012, PLoS neglected tropical diseases.

[42]  H. Takiff,et al.  Current Prospects for the Fluoroquinolones as First-Line Tuberculosis Therapy , 2011, Antimicrobial Agents and Chemotherapy.

[43]  Pia Abel zur Wiesch,et al.  Population biological principles of drug-resistance evolution in infectious diseases. , 2011, The Lancet. Infectious diseases.

[44]  M. Delarue,et al.  Structural Insights into the Quinolone Resistance Mechanism of Mycobacterium tuberculosis DNA Gyrase , 2010, PloS one.

[45]  G. Kahlmeter,et al.  Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data. , 2010, The Journal of antimicrobial chemotherapy.

[46]  S. Borrell,et al.  Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[47]  S. Niemann,et al.  Sequence Analyses of Just Four Genes To Detect Extensively Drug-Resistant Mycobacterium tuberculosis Strains in Multidrug-Resistant Tuberculosis Patients Undergoing Treatment , 2009, Antimicrobial Agents and Chemotherapy.

[48]  B. Levin,et al.  Exploring the role of the immune response in preventing antibiotic resistance. , 2009, Journal of theoretical biology.

[49]  Stefan Niemann,et al.  High Functional Diversity in Mycobacterium tuberculosis Driven by Genetic Drift and Human Demography , 2008, PLoS biology.

[50]  A. MacGowan,et al.  Clinical implications of antimicrobial resistance for therapy. , 2008, The Journal of antimicrobial chemotherapy.

[51]  C. D. Long,et al.  The Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis , 2006, Science.

[52]  Stefan Niemann,et al.  Variable host-pathogen compatibility in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Floyd E Romesberg,et al.  Open access, freely available online PLoS BIOLOGY Inhibition of Mutation and Combating the Evolution of Antibiotic Resistance , 2022 .

[54]  S. Hoffner,et al.  Drug-Susceptible Mycobacterium tuberculosis Beijing Genotype Does Not Develop Mutation-Conferred Resistance to Rifampin at an Elevated Rate , 2003, Journal of Clinical Microbiology.

[55]  J. Musser,et al.  Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. , 2000, The Journal of infectious diseases.

[56]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[57]  Robert H. Gilman,et al.  Rapid, Low-Technology MIC Determination with Clinical Mycobacterium tuberculosis Isolates by Using the Microplate Alamar Blue Assay , 1998, Journal of Clinical Microbiology.

[58]  B. D. de Jong,et al.  A four-month gatifloxacin-containing regimen for treating tuberculosis. , 2015, The New England journal of medicine.

[59]  Stefan Niemann,et al.  Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes , 2011 .

[60]  Lurias,et al.  MUTATIONS OF BACTERIA FROM VIRUS SENSITIVITY TO VIRUS RESISTANCE’-’ , 2003 .

[61]  P. Foster,et al.  Determining mutation rates in bacterial populations. , 2000, Methods.